Logo image of CTKB

CYTEK BIOSCIENCES INC (CTKB) Stock Overview

USA - NASDAQ:CTKB - US23285D1090 - Common Stock

4.065 USD
-0.13 (-3.21%)
Last: 10/29/2025, 3:53:03 PM

CTKB Key Statistics, Chart & Performance

Key Statistics
Market Cap517.15M
Revenue(TTM)196.03M
Net Income(TTM)-6401000
Shares127.22M
Float115.42M
52 Week High7.63
52 Week Low2.37
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.05
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO2021-07-23
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


CTKB short term performance overview.The bars show the price performance of CTKB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20

CTKB long term performance overview.The bars show the price performance of CTKB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CTKB is 4.065 USD. In the past month the price increased by 21.04%. In the past year, price decreased by -17.81%.

CYTEK BIOSCIENCES INC / CTKB Daily stock chart

CTKB Latest News, Press Relases and Analysis

CTKB Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 24.92 210.76B
DHR DANAHER CORP 27.65 152.65B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 143.51 46.81B
A AGILENT TECHNOLOGIES INC 26.28 40.60B
IQV IQVIA HOLDINGS INC 18.78 37.13B
MTD METTLER-TOLEDO INTERNATIONAL 34.09 28.72B
WAT WATERS CORP 28.05 20.42B
WST WEST PHARMACEUTICAL SERVICES 40.28 20.48B
MEDP MEDPACE HOLDINGS INC 41.05 16.49B
TEM TEMPUS AI INC N/A 15.48B
ILMN ILLUMINA INC 22.9 14.64B
ICLR ICON PLC 12.57 12.90B

About CTKB

Company Profile

CTKB logo image Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Company Info

CYTEK BIOSCIENCES INC

47215 Lakeview Boulevard

Fremont CALIFORNIA US

Employees: 688

CTKB Company Website

CTKB Investor Relations

Phone: 18779229835

CYTEK BIOSCIENCES INC / CTKB FAQ

What does CYTEK BIOSCIENCES INC do?

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.


What is the stock price of CYTEK BIOSCIENCES INC today?

The current stock price of CTKB is 4.065 USD. The price decreased by -3.21% in the last trading session.


Does CYTEK BIOSCIENCES INC pay dividends?

CTKB does not pay a dividend.


What is the ChartMill technical and fundamental rating of CTKB stock?

CTKB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the PE ratio for CTKB stock?

CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).


Can you provide the number of employees for CYTEK BIOSCIENCES INC?

CYTEK BIOSCIENCES INC (CTKB) currently has 688 employees.


What is the outstanding short interest for CYTEK BIOSCIENCES INC?

The outstanding short interest for CYTEK BIOSCIENCES INC (CTKB) is 5.44% of its float.


CTKB Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CTKB. When comparing the yearly performance of all stocks, CTKB is a bad performer in the overall market: 71.57% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CTKB Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CTKB. While CTKB has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CTKB Financial Highlights

Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 45.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1.3%
ROE -1.7%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%-2.18%
EPS 1Y (TTM)45.05%
Revenue 1Y (TTM)-0.85%

CTKB Forecast & Estimates

11 analysts have analysed CTKB and the average price target is 5.23 USD. This implies a price increase of 28.6% is expected in the next year compared to the current price of 4.065.

For the next year, analysts expect an EPS growth of -308% and a revenue growth -3.3% for CTKB


Analysts
Analysts78.18
Price Target5.23 (28.66%)
EPS Next Y-308%
Revenue Next Year-3.3%

CTKB Ownership

Ownership
Inst Owners63.24%
Ins Owners9.23%
Short Float %5.44%
Short Ratio7.62